High Court Biosimilar Drama Intact After Amgen-Apotex Denial
The U.S. Supreme Court's refusal Monday to review a major biosimilar ruling involving Amgen and Apotex doesn't necessarily mean that justices agree with the ruling, according to attorneys who predict that...To view the full article, register now.
Already a subscriber? Click here to view full article